Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Rhythm Pharmaceuticals Inc shares valued at $2,370,832 were sold by Smith Hunter C on Aug 12 ’25. At $96.33 per share, Smith Hunter C sold 24,611 shares. The insider’s holdings dropped to 116,915 shares worth approximately $11.28 million following the completion of this transaction.
Also, Smith Hunter C sold 3,477 shares, netting a total of over 333,792 in proceeds. Following the sale of shares at $96.00 each, the insider now holds 116,915 shares.
Before that, German Christopher Paul had sold 1,500 shares from its account. In a trade valued at $142,500, the Corporate Controller & CAO traded Rhythm Pharmaceuticals Inc shares for $95.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,500 shares, worth approximately $88954.56.
As published in their initiating research note from Goldman on July 10, 2025, Rhythm Pharmaceuticals Inc [RYTM] has been a Buy and the price target has been revised to $97. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. As of April 07, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for RYTM.
Analyzing RYTM Stock Performance
On last trading session, Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] plunged -1.41% to $96.48. The stock’s lowest price that day was $95.3002, but it reached a high of $97.545 in the same session. During the last five days, there has been a surge of approximately 4.33%. Over the course of the year, Rhythm Pharmaceuticals Inc shares have jumped approximately 116.91%. Shares of the company reached a 52-week high of $99.04 on 08/13/25 and a 52-week low of $45.90 on 04/07/25.
Support And Resistance Levels for Rhythm Pharmaceuticals Inc (RYTM)
According to the 24-hour chart, there is a support level at 95.34, which, if violated, would cause prices to drop to 94.20. In the upper region, resistance lies at 97.58. The next price resistance is at 98.69. RSI (Relative Strength Index) is 72.04 on the 14-day chart, showing overbought technical sentiment.
Is Rhythm Pharmaceuticals Inc subject to short interest?
Stocks of Rhythm Pharmaceuticals Inc saw a sharp steep in short interest on 2025-07-31 dropping by -0.34 million shares to 4.51 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 4.85 million shares. A decline of -7.52% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.86 of the overall float, the days-to-cover ratio (short ratio) decline to 4.86.
Which companies own the most shares of Rhythm Pharmaceuticals Inc (RYTM)?
In terms of Rhythm Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 97 in the next 12 months, down nearly -0.88% from the previous closing price of $97.86. Analysts anticipate Rhythm Pharmaceuticals Inc stock to reach 110 by 2025, with the lowest price target being 70. In spite of this, 5 analysts ranked Rhythm Pharmaceuticals Inc stock as Buy at the end of 2025. On January 02, 2025, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $80.
